Literature DB >> 20956959

Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.

J E Johansson1, M Remberger, V Lj Lazarevic, H Hallböök, A Wahlin, E Kimby, G Juliusson, H Omar, H Hägglund.   

Abstract

Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL.

Entities:  

Mesh:

Year:  2010        PMID: 20956959     DOI: 10.1038/bmt.2010.238

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

Review 1.  Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.

Authors:  A Rashidi; M Ebadi; A F Cashen
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 2.  Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

Authors:  M A Kharfan-Dabaja; M Hamadani; H Sibai; B N Savani
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

Review 3.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

Authors:  L Rasche; M Kapp; H Einsele; S Mielke
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

4.  EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.

Authors:  J Sanz; M Arango; L Senent; I Jarque; P Montesinos; A Sempere; I Lorenzo; G Martín; F Moscardó; E Mayordomo; M Salavert; C Cañigral; B Boluda; C Salazar; J L López-Hontangas; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483

Review 5.  Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

Review 6.  Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes.

Authors:  Ayumi Fujimoto; Ritsuro Suzuki
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

7.  Application of contrast-enhanced ultrasound in the diagnosis of post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation: A case report.

Authors:  Weinan Chen; Jianchun Li; Xiaoming Fan; Yanming Zhang; Li Wang; Yang Liu; Ailin Cui; Ligang Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.